Refine
Has Fulltext
- yes (45)
Is part of the Bibliography
- yes (45)
Year of publication
- 2020 (45) (remove)
Document Type
- Journal article (44)
- Doctoral Thesis (1)
Language
- English (45) (remove)
Keywords
- multiple myeloma (9)
- relapse (4)
- B cells (3)
- refractory (3)
- 18F-FDG PET/CT (2)
- cancer (2)
- inflammation (2)
- management (2)
- mortality (2)
- 11C-Methionine PET/CT (1)
- 3D culture (1)
- 68Ga-Pentixafor PET/CT (1)
- AKT-signaling (1)
- ALiOS (1)
- ASE formula (1)
- Adaptive cell transfer (1)
- Aspergillus fumigatus (1)
- Aspergillus sp. (1)
- Autologous hematopoietic stem cell transplantation (1)
- B cell (1)
- CAR T cell (1)
- CAR T cells (1)
- CCL3 (1)
- CCL4 (1)
- CCL5 (1)
- CCS (1)
- CD38 (1)
- CMV reactivation (1)
- COX2 expression (1)
- Candida sp. (1)
- Coronavirus Disease 2019 (1)
- Donor lymphocytes (1)
- EGFR (1)
- HB-EGF (1)
- HGF (1)
- HNSCC (1)
- Hämostase (1)
- Infectious complications (1)
- JCV (1)
- KRAS (1)
- MAPKAPK2 (1)
- MEK/ERK-signaling (1)
- MOR202 (1)
- MYC (1)
- Megakaryozyt (1)
- Met (1)
- Myeloma (1)
- NAFLD (1)
- NASH (1)
- NGS (1)
- NLRP3 (1)
- NRF2 (1)
- PD-L1 (1)
- PML (1)
- POU6F2-AS2 (1)
- Pom‐PAD‐Dara (1)
- Prodigy (1)
- Radiochemotherapy (1)
- Rectal cancer (1)
- Rhizopus arrhizus (1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (1)
- Surgery (1)
- Systemic sclerosis (1)
- T cell (1)
- T cells (1)
- TLR agonists (1)
- TNFSF14 (1)
- TNFSF4 (1)
- TSLP (1)
- Tdp-43 (1)
- Teichholz formula (1)
- Time interval (1)
- VCE (1)
- Western diet (1)
- Zink (1)
- acute lymphoblastic leukaemia (1)
- acute respiratory distress syndrome (1)
- adalimumab (1)
- adverse events (1)
- amplicon sequencing (1)
- amyotrophic lateral sclerosis (1)
- anticoagulation (1)
- antithrombotic therapy (1)
- anxiety (1)
- atrial fibrillation (1)
- autoimmune encephalitis (1)
- autoimmunity (1)
- autologous stem cell transplantation (1)
- axonal transcriptome (1)
- binding (1)
- blinatumomab (1)
- bone (1)
- bone marrow angiogenesis (1)
- bridging (1)
- cancer vaccines (1)
- capture (1)
- carfilzomib (1)
- cfRNA (1)
- chimeric antigen receptor (1)
- clinical trial (1)
- colonoscopy (1)
- common variable immunodeficiency (1)
- complications (1)
- corticosteroids (1)
- cytokines (1)
- daratumumab (1)
- ddPCR (1)
- definition (1)
- dendritic cells (1)
- discharge definition (1)
- donor-cell leukemia (1)
- drug screening (1)
- early detection (1)
- echocardiography (1)
- endothelial cells (1)
- extramedullary disease (1)
- fluorescence (1)
- fungal aerosolization (1)
- fungal infection (1)
- fungal infections (1)
- galactomannan (1)
- gene (1)
- genetic susceptibility (1)
- growth differentiation factor 15 (1)
- head and neck cancer (1)
- helicase (1)
- hematologic malignancies (1)
- hematological malignancies (1)
- hemodialysis (1)
- immune response (1)
- immune therapy (1)
- immunity (1)
- immuno-oncology (1)
- immunotherapeutics (1)
- immunotherapy (1)
- incidence (1)
- inflammasome (1)
- inflammation-induced tissue demage (1)
- interacts (1)
- interleukin 1 (1)
- interleukin 18 (1)
- invasive aspergillosis (1)
- kinease (1)
- left ventricular hypertrophy (1)
- left ventricular mass index (1)
- lenalidomide (1)
- lentiviral transduction (1)
- life-threatening side-effects (1)
- liquid biopsy (1)
- low molecular heparin (1)
- lymphocytes (1)
- mantle cell lymphoma (1)
- mechanosensing (1)
- mechanotransduction (1)
- melanoma malignancy (1)
- memory B cells (1)
- metabolic tumor volume (MTV) (1)
- methionine (1)
- molecular diagnosis (1)
- monocytes (1)
- multiplex PCR (1)
- muscle (1)
- music (1)
- myokines (1)
- nOAC (1)
- natural killer cell (1)
- newly diagnosed (1)
- nicotinamide (1)
- novel therapies (1)
- nuclear receptors (1)
- nucleotide excision repair (1)
- obinutuzumab (1)
- oral anticoagulants (1)
- organoids (1)
- osteokines adaptation (1)
- pancreatectomy (1)
- pathophysiology (1)
- pattern (1)
- personalised medicine (1)
- porcine large animal model (1)
- postoperative bleeding (1)
- pre-clinical models (1)
- primary immunodeficiencies (1)
- progression (1)
- prostaglandin E2 (1)
- pulmonary immune response (1)
- radiogenomics (1)
- recognition (1)
- relaxation (1)
- rheumatoid arhritis (1)
- safety (1)
- serum biomarkers (1)
- small bowel bleeding (1)
- smoldering myeloma (1)
- stem cell transplantation (1)
- stress level (1)
- subunit (1)
- sulfur (1)
- superior (1)
- surgical care (1)
- t-lymphocytes (1)
- thromboembolism (1)
- tocilizumab (IL-6 inhibitor) (1)
- total lesion glycolysis (TLG) (1)
- total lesion methionine uptake (TLMU) (1)
- toxicity (1)
- transactivation (1)
- tumor microenvironment (1)
- tumor-infiltrating (1)
- tumor-specific CD8+ T cells (1)
- tumor‐specific antigen (1)
- venetoclax (1)
- video capsule endoscopy (1)
- warfarin interruption (1)
Institute
- Medizinische Klinik und Poliklinik II (45) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 733297 (2)
- 19-COP-0031 (1)
- 641458 (1)
- 754658 (1)
- 847507 (1)
- 853988 (1)
- EU-1650-0006 (1)
This study aimed to explore the correlation between imaging patterns and clinical features in patients with smoldering multiple myeloma (SMM) who simultaneously underwent 18F-FDG, 11C-Methionine, and 68Ga-Pentixafor positron emission tomography/computed tomography (PET/CT). We retrieved and analyzed clinical characteristics and PET imaging data of 10 patients with SMM. We found a significant correlation between bone marrow (BM) plasma cell (PC) infiltration and mean standardized uptake values (SUV\(_{mean}\)) of lumbar vertebrae L2-L4 on 11C-Methionine PET/CT scans (r = 0.676, p = 0.031) and 68Ga-Pentixafor PET/CT scans (r = 0.839, p = 0.002). However, there was no significant correlation between BM involvement and SUV\(_{mean}\) of lumbar vertebrae L2-L4 on 18F-FDG PET/CT scans (r = 0.558, p = 0.093). Similarly, mean target-to-background ratios (TBR\(_{mean}\)) of lumbar vertebrae L2-L4 also correlated with bone marrow plasma cell (BMPC) infiltration in 11C-Methionine PET/CT (r = 0.789, p = 0.007) and 68Ga-Pentixafor PET/CT (r = 0.724, p = 0.018) PET/CT. In contrast, we did not observe a significant correlation between BMPC infiltration rate and TBR\(_{mean}\) in 18F-FDG PET/CT (r = 0.355, p = 0.313). Additionally, on 11C-Methionine PET/CT scans, we found a significant correlation between BMPC infiltration and TBR\(_{max}\) of lumbar vertebrae L2-L4 (r = 0.642, p = 0.045). In conclusion, 11C-Methionine and 68Ga-Pentixafor PET/CT demonstrate higher sensitivity than 18F-FDG PET/CT in detecting BM involvement in SMM.
\(^{11}\)C-methionine (\(^{11}\)C-MET) is a new positron emission tomography (PET) tracer for the assessment of disease activity in multiple myeloma (MM) patients, with preliminary data suggesting higher sensitivity and specificity than \(^{18}\)F-fluorodeoxyglucose (\(^{18}\)F-FDG). However, the value of tumor burden biomarkers has yet to be investigated. Our goals were to corroborate the superiority of \(^{11}\)C-MET for MM staging and to compare its suitability for the assessment of metabolic tumor burden biomarkers in comparison to \(^{18}\)F-FDG. Twenty-two patients with newly diagnosed, treatment-naïve symptomatic MM who had undergone \(^{11}\)C-MET and \(^{18}\)F-FDG PET/CT were evaluated. Standardized uptake values (SUV) were determined and compared with total metabolic tumor volume (TMTV) for both tracers: total lesion glycolysis (TLG) and total lesion \(^{11}\)C-MET uptake (TLMU). PET-derived values were compared to Revised International Staging System (R-ISS), cytogenetic, and serologic MM markers such as M component, beta 2 microglobulin (B2M), serum free light chains (FLC), albumin, and lactate dehydrogenase (LDH). In 11 patients (50%), \(^{11}\)C-MET detected more focal lesions (FL) than FDG (p < 0.01). SUVmax, SUVmean, SUVpeak, TMTV, and TLMU were also significantly higher in \(^{11}\)C-MET than in \(^{18}\)F-FDG (p < 0.05, respectively). \(^{11}\)C-MET PET biomarkers had a better correlation with tumor burden (bone marrow plasma cell infiltration, M component; p < 0.05 versus p = n.s. respectively). This pilot study suggests that \(^{11}\)C-MET PET/CT is a more sensitive marker for the assessment of myeloma tumor burden than \(^{18}\)F-FDG. Its implications for prognosis evaluation need further investigation.
One promising approach to treat hematologic malignancies is the usage of patient‐derived CAR T cells. There are continuous efforts to improve the function of these cells, to optimize their receptor, and to use them for the treatment of additional types of cancer and especially solid tumors. In this protocol, an easy and reliable approach for CAR T cell generation is described. T cells are first isolated from peripheral blood (here: leukoreduction system chambers) and afterwards activated for one day with anti‐CD3/CD28 Dynabeads. The gene transfer is performed by lentiviral transduction and gene transfer rate can be verified by flowcytometric analysis. Six days after transduction, the stimulatory Dynabeads are removed. T cells are cultured in interleukin‐2 conditioned medium for several days for expansion. There is an option to expand CAR T cells further by co‐incubation with irradiated, antigen‐expressing feeder cell lines. The CAR T cells are ready to use after 10 (without feeder cell expansion) to 24 days (with feeder cell expansion).
Common variable immunodeficiency (CVID) is the most common primary immunodeficiency in adults. It is associated with hypogammaglobulinemia, recurring infections and autoimmune phenomena. Treatment includes immunoglobulin substitution and immunosuppressants. Autoimmune neurological manifestations of CVID are rare and occur predominantly as granulomatous disease. We report the case of a 35-year-old woman with CVID who developed autoimmune encephalitis as demonstrated by double cerebral biopsy. Infectious or malignant causes could be excluded. Despite intensive immunosuppressive therapy with common regimens no significant improvement could be achieved. Ultimately, an autologous hematopoietic stem cell transplantation (HSCT) was performed, resulting in lasting complete remission of the encephalitis. To our knowledge, this is the first report of refractory autoimmune phenomena in CVID treated by autologous HSCT.
Organoid technology has rapidly transformed basic biomedical research and contributed to significant discoveries in the last decade. With the application of protocols to generate organoids from cancer tissue, organoid technology has opened up new opportunities for cancer research and therapy. Using organoid cultures derived from healthy tissues, different aspects of tumour initiation and progression are widely studied including the role of pathogens or specific cancer genes. Cancer organoid cultures, on the other hand, are applied to generate biobanks, perform drug screens, and study mutational signatures. With the incorporation of cellular components of the tumour microenvironment such as immune cells into the organoid cultures, the technology is now also exploited in the rapidly advancing field of immuno-oncology. In this review, I discuss how organoid technology is currently being utilised in cancer research and what obstacles are still to be overcome for its broader use in anti-cancer therapy.
Published experience with carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to assess the efficacy and safety of carfilzomib containing therapy regimens in EMD. We retrospectively analyzed 45 patients with extramedullary RRMM treated with carfilzomib from June 2013 to September 2019. The median age at the start of carfilzomib was 64 (range 40–80) years. Twenty (44%) and 25 (56%) patients had paraosseous manifestation and EMD without adjacency to bone, respectively. The serological overall response rate (ORR) was 59%. Extramedullary response was evaluable in 33 patients, nine (27%) of them achieved partial remission (PR) (ORR = 27%). In 15 (33%) patients, we observed no extramedullary response despite serological response. The median progression-free survival (PFS) and overall survival (OS) were five (95% CI, 3.5–6.5) and ten (95% CI, 7.5–12.5) months, respectively. EMD without adjacency to bone was associated with a significantly inferior PFS (p = 0.004) and OS (p = 0.04) compared to paraosseous lesions. Carfilzomib based treatment strategies showed some efficacy in heavily pretreated patients with extramedullary RRMM but could not overcome the negative prognostic value of EMD. Due to the discrepancy between serological and extramedullary response, evaluation of extramedullary response using imaging is mandatory in these patients.
Background and Aims: Colonoscopy as standard procedure in endoscopy is often perceived as uncomfortable for patients. Patient's anxiety is therefore a significant issue, which often lead to avoidance of participation of relevant examinations as CRC-screening. Non-pharmacological anxiety management interventions such as music might contribute to relaxation in the phase prior and during endoscopy. Although music's anxiolytic effects have been reported previously, no objective measurement of stress level reduction has been reported yet. Focus of this study was to evaluate the objective measurement of the state of relaxation in patients undergoing colonoscopy.
Methods: Prospective study (n = 196) performed at one endoscopic high-volume center. Standard colonoscopy was performed in control group. Interventional group received additionally self-chosen music over earphones. Facial Electromyography (fEMG) activity was obtained. Clinician Satisfaction with Sedation Instrument (CSSI) and Patients Satisfaction with Sedation Instrument (PSSI) was answered by colonoscopists and patients, respectively. Overall satisfaction with music accompanied colonoscopy was obtained if applicable.
Results: Mean difference measured by fEMG via musculus zygomaticus major indicated a significantly lower stress level in the music group [7.700(±5.560) μV vs. 4.820(±3.330) μV; p = 0.001]. Clinician satisfaction was significantly higher with patients listening to music [82.69(±15.04) vs. 87.3(±15.02) pts.; p = 0.001]. Patient's satisfaction was higher but did not differ significantly.
Conclusions: We conclude that self-chosen music contributes objectively to a reduced stress level for patients and therefore subjectively perceived satisfaction for endoscopists. Therefore, music should be considered as a non-pharmacological treatment method of distress reduction especially in the beginning of endoscopic procedures.
Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines
(2020)
Approximately 20% of multiple myeloma (MM) cases harbor a point mutation in KRAS. However, there is still no final consent on whether KRAS-mutations are associated with disease outcome. Specifically, no data exist on whether KRAS-mutations have an impact on survival of MM patients at diagnosis in the era of novel agents. Direct blockade of KRAS for therapeutic purposes is mostly impossible, but recently a mutation-specific covalent inhibitor targeting KRAS\(^{p.G12C}\) entered into clinical trials. However, other KRAS hotspot-mutations exist in MM patients, including the less common exon-4 mutations. For the current study, the coding regions of KRAS were deep-sequenced in 80 newly diagnosed MM patients, uniformely treated with three cycles of bortezomib plus dexamethasone and cyclophosphamide (VCD)-induction, followed by high-dose chemotherapy and autologous stem cell transplantation. Moreover, the functional impact of KRAS\(^{p.G12A}\) and the exon-4 mutations p.A146T and p.A146V on different survival pathways was investigated. Specifically, KRAS\(^{WT}\), KRAS\(^{p.G12A}\), KRAS\(^{p.A146T}\), and KRAS\(^{p.A146V}\) were overexpressed in HEK293 cells and the KRAS\(^{WT}\) MM cell lines JJN3 and OPM2 using lentiviral transduction and the Sleeping Beauty vector system. Even though KRAS-mutations were not correlated with survival, all KRAS-mutants were found capable of potentially activating MEK/ERK- and sustaining PI3K/AKT-signaling in MM cells.
Background: Video capsule endoscopy (VCE) is the standard procedure for a work-up of a suspected bleeding source after negative gastroscopy and colonoscopy. Popularity of this procedure increased in the last decade. In this work we aimed to identify the changes in patient characteristics and how those changes influence bleeding related findings. In particular the assumed higher risk of gastrointestinal bleeding of the new oral anticoagulants (nOAC) compared to phenprocoumon was of interest.
Methods: Consecutive VCE examinations performed at our center from January 2004 to March 2018 were identified retrospectively. Baseline characteristics of the patients, VCE results and treatment that was initiated were analyzed.
Results: 560 VCE were included in the analysis. The rate of VCE per month increased from 2.3/month in the period of January 2004 – December 2012 up to 5.0/month in January 2013 – March 2018. Accompanied by this increase the examined patients suffered from significantly more comorbidities (72 vs. 82%, p 0.001) and used a higher number of bleeding-related drugs (47 vs. 66%, p <0.001), especially nOACs. Age above 65 and bleeding-related drugs were significantly associated with angiodysplasias found on VCE examinations. NOACs and phenprocoumon showed no difference in their correlation to angiodysplasias.
Conclusion: This single center retrospective analysis revealed a steep increase in VCE examinations over the last years with an increase in the prevalence of comorbidities and the use of bleeding-related drugs. Interestingly, use of both nOACs and phenprocoumon did not result in a significant higher rate of angiodysplasias in the VCE.